MonoSol Rx signs agreement with Hikma for thin film products in the Middle East

Published: 18-Dec-2008
Regulatory Research & Development

MonoSol Rx has entered into an agreement for thin film pharmaceutical products with Hikma Pharmaceutical, a manufacturer of generic and in-licensed pharmaceutical products.


MonoSol Rx has entered into an agreement for thin film pharmaceutical products with Hikma Pharmaceutical, a manufacturer of generic and in-licensed pharmaceutical products.

MonoSol Rx is the developer of PharmFilm technology and a drug delivery company specialising in dissolving thin film pharmaceutical products.

Under terms of the agreement, Hikma will exclusively distribute in the Middle East three products based on PharmFilm technology. Hikma will obtain all registrations and approvals required to market the products throughout the region.

MonoSol Rx will receive milestone payments and payments for the purchase of product supply.

Mark Schobel, president and chief executive of MonoSol Rx, said: "In addition to expanding our reach into new geographic territories, our partnership with Hikma further validates our proprietary PharmFilm technology, leadership in thin film drug development, and growing intellectual property portfolio."

  • Companies:
  • Hikma Pharmaceuticals
  • MonoSol Rx
See more

You may also like

Regulatory

Status update on ANDA for generic Advair Diskus (VR315 [US])

Read more
Vectura Group, an industry leading inhalation CDMO, confirms the announcement made by its partner Hikma Pharmaceuticals

Trending Articles

  1. Thermo Fisher Scientific reveals MagMax Sequential DNA/RNA Kit to advance blood cancer research The kit combines DNA and RNA isolation chemistries into a single kit, simplifying sample extraction for a broad range of downstream molecular applications
  2. Asahi Kasei Pharma grows its global portfolio with anti-CX3CR1 license The licensing deal with Chiome enhances its open innovation platform
  3. You need to be a subscriber to read this article.
    Click here to find out more.
    Merck jumps on the GLP-1 therapeutic bandwagon by licensing Hansoh Pharma's HS-10535 Merck will be responsible for the development, manufacture and commercialisation of the investigational preclinical oral GLP-1 receptor agonist
  4. Medac and chiron develop organ-on chip tech for animal free drug testing The companies aim to develop an animal-free pharmaceutical testing method that utilises organ-on chip technology, and will be used in rheumatoid arthritis drug testing

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

Regulatory

Status update on ANDA for generic Advair Diskus (VR315 [US])

Vectura Group, an industry leading inhalation CDMO, confirms the announcement made by its partner Hikma Pharmaceuticals
Regulatory

Hikma launches Dalfampridine Extended-release tablets

Hikma Pharmaceuticals, formerly known as West-Ward Pharmaceuticals, has launched Dalfampridine Extended-release tablets, 10 mg, the generic therapeutic equivalent to Ampyra
Regulatory

Hikma enters settlement agreement with Jazz for sodium oxybate

Jazz will grant Hikma and West-Ward the right to sell an authorised generic of Xyrem in the US
Research & Development

Blood cancer charity thanks Hikma Pharmaceuticals for its support

DKMS is dedicated to the fight against blood cancer, recruiting stem cell donors and providing second chances at life
Manufacturing

Hikma announces successful resolution to FDA warning letter at its Portugal facility

Will enable Hikma to accelerate the introduction of new products to the market
Regulatory

Hikma receives warning letter from US FDA

Over environmental monitoring issues at its plant in Portugal
Research & Development

MidaSol Therapeutics signs research collaboration with major US pharmaceutical company

Midatech and MonoSol Rx joint venture to develop new treatment for diabetes
Subscribe now